Nanoscope Therapeutics
Bedford
About Nanoscope Therapeutics
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. They utilize ambient light-sensitive molecules to re-sensitize the retina toward a low light level. Its light-assisted gene therapy is highly targeted to geographic atrophies without perturbing the intact retina circuitry.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $3.5M
- Funding stage: Early Stage Venture
- Last round: Grant (Sep 2021)
- Website: nanostherapeutics.com
- Phone: 817-719-2692
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/nanoscope-therapeutics-18141 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.